Loading
companiesCompany
EcoR1 Capital
EcoR1 Capital is a San Francisco investment fund that only invests in biotech, from private rounds to listed companies, and often leads the crossover financings of cancer drug developers.
Overview
EcoR1 Capital is a biotech-focused investment firm based in San Francisco, founded in 2013 by Oleg Nodelman, investing across private and public companies with a long holding period and a scientific due diligence model. It is a frequent lead or co-lead in crossover rounds and follow-on offerings for clinical-stage oncology companies. Portfolio links in OnCo are derived from the startup records that name it.
Portfolio (2)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Neogene Therapeutics Amsterdam, NL | Acquired | cell therapy | Acquisition 2023, $320M | |
| Tango Therapeutics Boston, MA, US | Public | biotech | Pancreatic ductal adenocarcinomaNon-small-cell lung cancerGlioma & glioblastoma | IPO 2021, $353M |
Similar pages
- CompanyPolaris Partners
Shares Neogene Therapeutics and the tag vc.
- CompanyJeito Capital
Shares Neogene Therapeutics and the tag vc.
- CompanySamsara BioCapital
Shares Tango Therapeutics and the tag vc.
- CompanyVida Ventures
Shares Neogene Therapeutics and the tag vc.
- CompanyCormorant Asset Management
Shares Tango Therapeutics and the tag vc.
- CompanyBoxer Capital
Shares Tango Therapeutics and the tag vc.
- CompanyLogos Capital
Shares Tango Therapeutics and the tag vc.
- CompanyBain Capital Life Sciences
Shares Tango Therapeutics and the tag vc.